---
title: The Sponsor's Obligations in Clinical Investigations Under MDR Article 62(4)
description: MDR Article 62(4) sets out what the sponsor of a clinical investigation must do. Here is the obligations list and how it lands on a startup sponsor.
authors: Tibor Zechmeister, Felix Lenhard
category: Clinical Evaluation & Investigations
primary_keyword: sponsor obligations clinical investigations MDR
canonical_url: https://zechmeister-solutions.com/en/blog/sponsor-obligations-clinical-investigations-mdr
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# The Sponsor's Obligations in Clinical Investigations Under MDR Article 62(4)

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

> **The sponsor of a clinical investigation under MDR is the legal entity that takes responsibility for the initiation, management, and financing of the investigation. MDR Article 62(4) sets out the core obligations the sponsor must satisfy before and during the study: scientific soundness of the design, protection of subject rights and safety, a justified risk-benefit balance, a written clinical investigation plan, informed consent, ethics committee approval, reliable and robust data, insurance or indemnification arrangements to cover damages, and a qualified team to run the study. The broader framework of Articles 62 to 82 of Regulation (EU) 2017/745, Annex XV, and the harmonised standard EN ISO 14155:2020+A11:2024 operationalise those obligations in detail. None of them scale down for a two-person startup — the obligations are the same as for a multinational, and the discipline of meeting them is the real cost of running a clinical investigation.**

**By Tibor Zechmeister and Felix Lenhard. Last updated 10 April 2026.**

---

## TL;DR

- The sponsor is the legal entity responsible for the initiation, management, and financing of a clinical investigation. For a startup, the sponsor is almost always the company itself.
- MDR Article 62(4) lists the core conditions every clinical investigation conducted to demonstrate conformity must satisfy — these are the obligations the sponsor personally carries.
- The obligations cover scientific soundness, subject protection, risk-benefit justification, a written clinical investigation plan, informed consent, ethics committee approval, reliable data, qualified personnel, and insurance or indemnification arrangements.
- Articles 62 to 82 and Annex XV of Regulation (EU) 2017/745 and EN ISO 14155:2020+A11:2024 fill in the operational detail.
- Sponsor obligations do not scale down for small teams. A two-person sponsor carries the same legal weight as a multinational.
- The most common failure mode for startup sponsors is discovering, in week four of the investigation, that an obligation they did not fully read is already being violated.

---

## Who the sponsor is and why the word matters

In every clinical investigation under MDR, one legal entity takes responsibility for the study. That entity is the sponsor. The sponsor initiates the investigation, manages the investigation, and funds the investigation. The sponsor signs the application to the competent authority. The sponsor's name is on the ethics committee submission. The sponsor is the party the Regulation holds accountable if anything goes wrong.

For a startup, this is almost always the company itself. The founders may not have written the protocol with their own hands — a contract research organisation, a clinical research associate, or a regulatory consultant may have done much of the drafting — but the legal sponsor is the company whose name appears on the application, and the obligations sit on that company regardless of who did the typing.

This is one of the places where founders most often misread the situation. Hiring a CRO does not transfer sponsor obligations. A CRO can execute specific tasks on the sponsor's behalf under a written contract, but the sponsor remains accountable under MDR Article 62 and the rest of the Chapter VI framework. A sponsor who believes they have outsourced responsibility discovers otherwise the first time a serious adverse event has to be reported within 24 hours and nobody on the founding team knows which email address it goes to.

The word "sponsor" is a legal term in the MDR and in EN ISO 14155:2020+A11:2024. It means what the Regulation says it means, not what it means in colloquial English. A sponsor is not a financial backer. A sponsor is the responsible party.

## MDR Article 62(4) — the obligations list

MDR Article 62(4) is the spine of sponsor obligations for a clinical investigation conducted to demonstrate conformity. It lists a set of conditions that every such investigation must satisfy. Read as obligations on the sponsor, they are:

**(a) Scientific soundness.** The clinical investigation must be designed and conducted in such a way that the rights, safety, dignity, and well-being of subjects are protected and prevail over all other interests, and the clinical data generated are scientifically valid, reliable, and robust. The sponsor owns this. A design that cannot answer its own scientific question is not a sponsor's excuse — it is the sponsor's failure.

**(b) Justified risk-benefit balance.** The foreseeable risks and inconveniences to subjects must be weighed against the anticipated benefits to subjects and to public health, and the benefits must justify the risks. The sponsor produces this analysis in writing, anchored in the risk management file and the pre-clinical evidence package.

**(c) Subject protection takes precedence.** The rights, safety, dignity, and well-being of subjects prevail over the interests of science and society. This is not a slogan — it is the test against which every sponsor decision during the study is judged.

**(d) Informed consent.** The subject, or their legal representative where applicable, has given informed consent in accordance with Article 63 and the surrounding provisions. The sponsor designs the consent process, produces the consent documents, and ensures the sites collect consent correctly.

**(e) Ethics committee approval.** The clinical investigation has received positive opinion from the ethics committee of the member state or states in which it will be conducted. The sponsor prepares the submission, answers the committee's questions, and holds the approval before the first subject is enrolled.

**(f) Qualified personnel.** The investigator conducting the clinical investigation is a person exercising a profession that is recognised in the member state for the role of investigator, and appropriately qualified. The sponsor selects investigators, verifies their qualifications, and documents the qualification check.

**(g) Reliable and robust data.** The clinical data generated are scientifically valid, reliable, and robust. The sponsor owns data quality, data management, monitoring, and the integrity of the database.

**(h) A written clinical investigation plan.** The investigation is conducted on the basis of a clinical investigation plan, and the plan is followed. The sponsor writes the plan, locks it before authorisation, and manages amendments under Article 75.

**(i) Protection of subject information.** Subject data is protected and used only for the purposes authorised. The sponsor builds the data handling procedures that make this real.

**(j) Damages compensation.** Subjects are covered by insurance or indemnity arrangements that compensate for damage arising from participation in the investigation. The sponsor arranges the insurance or the equivalent indemnification before the investigation begins.

Those ten points are the substantive content of Article 62(4) read as sponsor obligations. They are not a checklist the sponsor delegates — they are the contract the sponsor signs when the application goes to the competent authority.

## The wider framework — Articles 62 to 82 and Annex XV

Article 62(4) is the spine, but the full skeleton of sponsor obligations is spread across Articles 62 to 82 and Annex XV of Regulation (EU) 2017/745.

**Article 63 — Informed consent.** The sponsor is responsible for the consent process and the consent documents, including the requirements for comprehensibility, the right to withdraw, and the special provisions for specific populations.

**Articles 64 to 68 — Specific populations.** If the investigation enrols incapacitated subjects, minors, pregnant or breastfeeding women, or subjects in emergency situations, the sponsor must build in the additional protections these articles require.

**Article 70 and surrounding provisions — Application to the competent authority.** The sponsor prepares and submits the application dossier. The content is specified in Annex XV.

**Article 72 — Conduct obligations.** Once the investigation is authorised, the sponsor is responsible for the conduct of the investigation in accordance with the clinical investigation plan, the Regulation, and the applicable standards. Article 72 is where the day-to-day running of the study lands legally on the sponsor.

**Article 75 — Substantial modifications.** Changes to the investigation after authorisation — to the design, the plan, the sites, the investigators, or other substantial aspects — must go through a defined notification and authorisation procedure before they take effect. The sponsor operates this procedure.

**Article 77 — End of investigation reporting.** The sponsor submits a clinical investigation report at the end of the investigation, or after a halt or early termination, within the timeframes the Regulation defines.

**Article 80 — Adverse event recording and reporting.** Serious adverse events and certain device deficiencies that occur during the investigation must be recorded and reported to the competent authority within short, defined timelines. The sponsor operates the vigilance chain for the study.

**Annex XV — Documentation.** The content of the clinical investigation plan, the investigator's brochure, the documentation of the device under investigation, and the reporting obligations are specified in detail. The sponsor produces every one of these documents.

**EN ISO 14155:2020+A11:2024 — Good Clinical Practice.** The harmonised standard that operationalises all of the above. Sections on sponsor responsibilities, investigator responsibilities, ethics committee interactions, clinical investigation plan content, data management, monitoring, adverse event handling, reporting, and archiving. The standard is the operational floor that a sponsor uses to meet the legal obligations of Articles 62 to 82 and Annex XV.

A sponsor who has read Article 62(4) but not the rest of Chapter VI and not EN ISO 14155:2020+A11:2024 has read the table of contents, not the book.

## Insurance and damages compensation

The damages compensation obligation deserves its own section because it is the one founders underestimate most.

Article 62(4) requires that subjects be covered by insurance or equivalent indemnification arrangements against damage arising from their participation in the investigation. National law in each member state where the investigation runs may add specific requirements on top — minimum coverage amounts, acceptable insurance providers, and documentation that must be produced to the competent authority and to the ethics committee before authorisation.

Insurance for medical device clinical investigations is not the same product as general liability insurance. It is a specialised line, the underwriting takes time, and the cost is not trivial. A sponsor who begins the insurance conversation two weeks before planned enrolment discovers that the quoting process alone can take longer than that, and the resulting premium can reshape the study budget.

Three practical rules for startup sponsors on insurance:

First, start the conversation the moment the clinical investigation plan stabilises. Brokers who specialise in clinical trial cover need the protocol, the sample size, the endpoints, the sites, and the risk profile of the device to quote meaningfully.

Second, verify the policy matches the requirements of the member state where the study will run. A pan-European policy is possible but not automatic. A member state where the national minimum coverage is not met by the policy blocks authorisation.

Third, keep the insurance certificate in the application dossier and in the site files at every participating site. Monitors will ask for it. Ethics committees will ask for it. The competent authority will ask for it.

## Oversight, monitoring, and the sponsor's conduct role

Under Article 72 and EN ISO 14155:2020+A11:2024, the sponsor is responsible for overseeing the conduct of the investigation. Oversight is not passive. It means the sponsor actively verifies that the sites are following the clinical investigation plan, that informed consent is being collected correctly, that device accountability is being maintained, that adverse events are being captured and reported within the Article 80 timelines, and that data are being entered accurately and on time.

The mechanism for this oversight is the monitoring plan, which is part of the clinical investigation plan required by Annex XV. A good monitoring plan specifies who monitors (by name and qualification), how often, what is checked, what triggers an unscheduled visit, and how findings are documented and followed up. A monitoring plan that cannot be executed by the sponsor's actual team is a plan that will be violated, and violated monitoring plans surface as findings at the final inspection or the Notified Body review of the clinical evaluation.

For a small sponsor, two patterns work. Either the sponsor builds internal monitoring capacity — one person, qualified, dedicated — and accepts that this is a real role on the team. Or the sponsor contracts monitoring to a CRO or an independent clinical research associate under a written agreement that specifies the deliverables and the escalation path. What does not work is assuming that the site will monitor itself, or that monitoring can be done in spare hours by a founder who is also running the company.

## Adverse event handling — the obligation that runs 24/7

Article 80 governs the recording and reporting of serious adverse events and certain device deficiencies that occur during a clinical investigation. The reporting timelines are short. The responsibility is absolute. And the clock does not stop for weekends, holidays, or a founder's travel schedule.

The sponsor must have a written procedure — in the clinical investigation plan and in the sponsor's QMS — for how adverse events are captured at the site, communicated to the sponsor, assessed for seriousness and causality, reported to the competent authority and the ethics committee where required, and followed up until resolution. The procedure must name specific people and specific backup people. A single point of failure in the adverse event chain is not acceptable.

This is the obligation where the gap between "I have a CRO" and "I am the sponsor" shows up most clearly. A CRO can support the reporting. The sponsor authorises the report, is legally accountable for the content, and faces the competent authority if the report is late or wrong. Founders who take sponsor responsibility seriously build a 24/7 adverse event handling chain before the first subject is enrolled, and they test it.

## The small-team sponsor reality

Almost every startup running a clinical investigation is a small-team sponsor. Two to ten people. One regulatory lead, often the CTO or a part-time regulatory affairs contractor. One clinical lead, sometimes a founder with a clinical background, sometimes an external advisor. A principal investigator at each site who is independent of the sponsor.

Small-team sponsors can meet every obligation in Article 62(4), Articles 62 to 82, Annex XV, and EN ISO 14155:2020+A11:2024. What they cannot do is meet them by accident. Three practices separate sponsors who succeed at this from sponsors who do not.

First, the sponsor reads the obligations — personally, cover to cover, not in summary — and builds a traceability matrix that maps every obligation to a named person, a named procedure, and a named document. Nothing is left to "someone on the team will handle that."

Second, the sponsor negotiates CRO and consultant contracts with the obligations list in hand, not with a generic services scope. Every sponsor obligation that is delegated in practice is assigned in writing, and the boundary of delegation is explicit. The sponsor keeps the accountability; the CRO takes the specific task.

Third, the sponsor invests in the boring parts — version control, SOPs, training records, the adverse event escalation drill — before the investigation opens. These are the parts that fail first when the investigation is running and the team is tired, and they are the parts that the competent authority inspects when something goes wrong.

## Common gaps we see in startup sponsor readiness

A short list of the obligations we see startup sponsors miss, underestimate, or handle late.

**Insurance started too late.** The quoting conversation begins three or four weeks before enrolment, and the policy is not in place when the ethics committee asks for the certificate.

**No written delegation of sponsor tasks to the CRO.** The scope of services sits in a generic master services agreement, not in a document tied to the specific sponsor obligations the sponsor intends to delegate.

**Investigator qualification checks not documented.** The principal investigator at each site is clearly qualified, but the sponsor's file does not contain the CVs, the GCP training certificates, and the qualification assessment the sponsor performed.

**Monitoring plan that overcommits.** The clinical investigation plan promises monthly on-site monitoring visits, the sponsor has no monitor named, and the plan is broken from the first week.

**Adverse event chain with a single point of failure.** One person handles Article 80 reporting, no backup is named, and the first serious adverse event arrives the week that person is on holiday.

**End-of-investigation report deferred.** The sponsor treats the end-of-investigation report under Article 77 as a retrospective task, rather than a planned deliverable with the same discipline as any other regulatory submission.

Each one of these is avoidable. Each one, in our experience, shows up in at least one project per year when the sponsor did not take the Article 62(4) obligations list seriously enough to operationalise it before the investigation opened.

## The Subtract to Ship angle

Sponsor obligations are one of the places in MDR where Subtract to Ship explicitly does not cut. Every obligation in Article 62(4), Articles 62 to 82, Annex XV, and EN ISO 14155:2020+A11:2024 is required. None of them come out in the name of lean execution.

What Subtract to Ship does cut is the ceremony around the obligations. A traceability matrix on one page beats a forty-page sponsor obligations handbook that nobody reads. A two-person adverse event chain with a documented escalation drill beats a ten-person committee structure that exists only on the org chart. A clinical investigation plan of thirty to fifty pages that the team can actually follow beats a ninety-page plan that the investigators skim. Our methodology pillar [The Subtract to Ship Framework for MDR Compliance](/blog/subtract-to-ship-framework-mdr) walks through the discipline.

The test remains the same: every activity the sponsor runs must trace to a specific article, annex, or standard clause. For clinical investigations, the test passes for more activities than founders expect — because sponsor obligations are dense, and most of them are non-negotiable. The Subtract to Ship angle is not to skip them; it is to operationalise them without padding.

## Reality Check — Where do you stand?

1. Have you read Article 62(4), Articles 62 to 82, and Annex XV of Regulation (EU) 2017/745 personally, or only through someone else's summary?
2. Do you have a written traceability matrix that maps every Article 62(4) obligation to a named person on your team and a named procedure in your QMS?
3. Is the sponsor entity on the application clearly identified, and does the founding team understand that this entity — not a CRO — carries the legal obligations?
4. Is your insurance or indemnification arrangement in place, with documentation in the dossier, before the application goes to the competent authority?
5. Have you verified that your insurance policy meets the national requirements of every member state where the investigation will run?
6. Does your monitoring plan name the monitor, state the frequency, and match the actual capacity of the sponsor team or the contracted CRO?
7. Is your adverse event handling chain under Article 80 documented, staffed with a primary and a backup, and tested before the first subject is enrolled?
8. Are investigator qualification checks — CVs, GCP training, qualification assessment — in the sponsor's file for every principal investigator at every site?
9. Is the end-of-investigation reporting obligation under Article 77 on the project plan with a named owner and a target date?
10. If a competent authority inspector walked into your office tomorrow and asked to see the sponsor's file for this investigation, would it be ready?

## Frequently Asked Questions

**Who is the sponsor of a clinical investigation under MDR?**
The sponsor is the legal entity that takes responsibility for the initiation, management, and financing of the clinical investigation. For a startup running a study on its own device, the sponsor is almost always the company itself. The sponsor is the party the Regulation holds legally accountable for compliance with Article 62(4), Articles 62 to 82, Annex XV, and EN ISO 14155:2020+A11:2024 — regardless of which tasks are executed by CROs, consultants, or site staff.

**Can a startup outsource sponsor obligations to a CRO?**
Specific tasks, yes. Legal accountability, no. A contract research organisation can execute drafting, monitoring, data management, site management, and pharmacovigilance functions under a written agreement. But the sponsor obligations under MDR Article 62(4) and the surrounding provisions remain with the legal sponsor. A CRO supports the sponsor; it does not replace the sponsor. Any contract that implies otherwise is misrepresenting the Regulation.

**What does MDR Article 62(4) actually require?**
Article 62(4) lists the conditions every clinical investigation conducted to demonstrate conformity must satisfy: scientific soundness of the design, protection of subject rights and safety, a justified risk-benefit balance, a written clinical investigation plan that is followed, informed consent under Article 63, ethics committee approval, qualified investigators, reliable and robust data, subject data protection, and insurance or indemnification for damages. These map directly to sponsor obligations — the sponsor is the party that has to satisfy each one.

**Is insurance for a clinical investigation expensive?**
It depends on the device risk profile, the number of subjects, the duration of follow-up, and the member states where the study runs. Specialised brokers underwrite clinical trial cover for medical devices, and the quoting process takes time. Startups typically find that the premium is a meaningful line in the study budget but not the dominant one — and that starting the conversation late is far more expensive than the policy itself, because it delays authorisation.

**What happens if a sponsor misses the Article 80 adverse event reporting timeline?**
Missing the timeline is a compliance failure that the competent authority can act on. Consequences range from a warning, to a requirement to submit a corrective action plan, to suspension of the investigation, depending on severity and on the sponsor's response. Beyond the regulatory consequences, a missed serious adverse event report damages the sponsor's credibility with the authority and the ethics committee for every future submission. The Article 80 chain is one of the few parts of the investigation where there is no margin for error.

**Does a small sponsor have the same obligations as a large one?**
Yes. MDR Article 62(4), Articles 62 to 82, Annex XV, and EN ISO 14155:2020+A11:2024 do not distinguish between sponsor sizes. A two-person sponsor carries the same legal weight as a multinational. What differs is the scale of the investigation each one tends to run — a small sponsor typically runs a focused, single-device study, and the obligations apply in proportion to that scope. The discipline of meeting them is the same either way.

**When does the sponsor's role end?**
After the clinical investigation report under Article 77 is submitted, after the database is locked, after the archiving obligations of EN ISO 14155:2020+A11:2024 and national law are in place, and after any post-investigation follow-up specified in the clinical investigation plan is complete. Archiving obligations in particular extend for many years after the investigation closes, and the sponsor carries them for the whole period. The sponsor's role does not end when the last subject visit is done.

## Related reading

- [What Is a Clinical Investigation Under MDR? When Your Startup Needs to Run a Study](/blog/what-is-clinical-investigation-mdr) — the definitional groundwork and the when-is-it-required question.
- [MDR Article 62 General Requirements for Clinical Investigations](/blog/mdr-article-62-general-requirements) — the article-by-article treatment of the core provision.
- [How to Design a Clinical Investigation for a MedTech Startup](/blog/design-clinical-investigation-startup) — the design decisions that precede sponsor execution.
- [Writing a Clinical Investigation Plan (CIP) Under MDR Article 62](/blog/write-clinical-investigation-plan-cip) — the document the sponsor owns and the ethics committee judges.
- [Investigator's Brochure Under MDR Annex XV](/blog/investigators-brochure-mdr-annex-xv) — the companion document to the CIP that the sponsor produces.
- [Informed Consent Under MDR Article 63](/blog/informed-consent-mdr-article-63) — the consent obligation the sponsor operationalises.
- [Adverse Event Reporting Under MDR Article 80](/blog/adverse-event-reporting-mdr-article-80) — the vigilance chain the sponsor runs during the investigation.
- [Ethical Approval for Clinical Investigations Under MDR](/blog/ethical-approval-clinical-investigations) — the ethics committee pathway the sponsor navigates.
- [How to Run a Lean Clinical Investigation as a Startup with Limited Budget](/blog/lean-clinical-investigation-startup) — the operational companion for sponsors with constrained runways.
- [The Subtract to Ship Framework for MDR Compliance](/blog/subtract-to-ship-framework-mdr) — the methodology behind how we approach sponsor execution.

## Sources

1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, Article 62 (general requirements regarding clinical investigations conducted to demonstrate conformity of devices), Article 62(4) (conditions that every conformity clinical investigation must satisfy), Articles 63 to 82 (clinical investigations framework, including informed consent, specific populations, application, sponsor conduct, substantial modifications, end-of-investigation reporting, and adverse event reporting), Annex XV (clinical investigations). Official Journal L 117, 5.5.2017.
2. EN ISO 14155:2020+A11:2024 — Clinical investigation of medical devices for human subjects — Good clinical practice.

---

*This post sits in the Clinical Evaluation & Clinical Investigations cluster of the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. If you are taking on sponsor obligations for a clinical investigation under MDR Article 62(4) and want to pressure-test your readiness before the application goes to the competent authority, Zechmeister Strategic Solutions works with founders on exactly that review — obligation by obligation, document by document, name by name.*

---

*This post is part of the [Clinical Evaluation & Investigations](https://zechmeister-solutions.com/en/blog/category/clinical-evaluation) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*